A Molecular Docking Study Of Human STEAP2 For The Discovery Of New Potential Anti-Prostate Cancer Chemotherapeutic Candidates
T. Ongaba, N. Christian, N. J. Nakiddu
This study uses molecular docking to identify FDA-approved drugs that bind to STEAP2, a prostate cancer biomarker, with Triptorelin and Leuprolide showing the strongest interactions.
bioRxiv · Sep 2, 2021 · PreprintCancer Biology